English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResults of 16-Center REVIVE trial published in The New England Journal of Medicine
Tag: Blood Cancer
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.
Francine Foss, MD, in honor of Blood Cancer Awareness Month
As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.
New insights to enhance treatment and diagnosis of blood cancer
A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.
Ketogenic diet and its effects on tumour growth and ‘wasting syndrome’
Professor Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore at the National University of Singapore, together with Assistant Professor Tobias Janowitz, Principal Investigator at the Cold Spring Harbor Laboratory in New York, and an international group of researchers from the USA and UK, have discovered that ketogenic diets delay tumour growth but accelerate cachexia, a wasting syndrome, an unintended side effect that could cause death.
Does That MDS Diagnosis Need a Second Opinion?
Blood disorders known as myelodysplastic syndromes/neoplasms are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other potentially harmful consequences. A new study highlights the vital need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of blood cancers.
Study: Blood stem cell diversity arises in embryonic development
All humans have a diverse set of blood stem cell types that help govern overall health. As people age, they tend to lose this diversity, increasing their risk for blood cancers, cardiovascular disease and all-causes death. Yale School of Medicine…
Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Research identifies new target that may prevent blood cancer
An international coalition of biomedical researchers co-led by Alexander Bick, MD, PhD, at Vanderbilt University Medical Center has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer. The technique, called PACER, led to the identification of a gene that, when activated, drives clonal expansion.
A promising outlook: CAR T cells improve patient quality of life
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy.
Scientists discover new lead in hunt for myeloma drug
A molecule involved in fat transport and metabolism is key to the progression of the malignant blood cancer multiple myeloma, researchers report today in eLife.
National Comprehensive Cancer Network Announces Collaboration with Blood Cancer Experts in Poland
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
Multiplication on, multiplication off: Targeting an enzymatic switch to develop oncology drugs
Interdisciplinary research highlighted lipid-protein interaction as a new avenue for oncology drug development, demonstrating its functionality by designing small molecule-based inhibitors to target acute myeloid leukemia.
Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow Transplant
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.
Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Penn Medicine at the 2022 ASH Meeting
Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in blood cancer research and treatment at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13.
UVA blood cancer research points to new treatment for bone marrow cancer
Pioneering research into the chronic inflammation often seen in certain blood cancers has identified a promising treatment approach for myelofibrosis, a potentially deadly bone marrow cancer.
NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
Blood cancer scientists developing powerful new tools to improve diagnosis and treatment for patients
Australian researchers will use new technology to improve the diagnosis and treatment of blood cancers, which affect 1.24 million people globally, including 720,000 who die from leukemia, lymphoma or myeloma each year.
There’s a Better Way to Detect High-Risk Medications in Older Adults with Cancer According to New Study in JNCCN
Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.
Stanford cancer team halts growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3
Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
Scientists discover genes that affect the risk of developing pre-leukaemia
The discovery of 14 inherited genetic changes which significantly increase the risk of a person developing a symptomless blood disorder associated with the onset of some types of cancer and heart disease is published today in Nature Genetics. The finding, made in one of the largest studies of its kind through genetic data analysis on 421,738 people, could pave the way for potential new approaches for the prevention and early detection of cancers including leukaemia.
Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine
Most patients in the study mounted immune responses after a booster dose, and no patient with antibody responses died from COVID-19.
New Work Upends Understanding of How Blood Is Formed
The origins of our blood may not be quite what we thought. Using cellular “barcoding” in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children’s Hospital led the study, published in Nature on June 15.
Mount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
Immunity boosting treatment enhances CAR-T cell therapy for blood cancers
A new study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.
Study finds COVID-19 breakthrough cases can be severe for people with blood cancers
People with blood cancers are at a higher risk than healthy individuals for severe and life-threatening COVID-19 illness; furthermore, research suggests that they do not always achieve optimal protection from vaccination.
Albert Einstein Cancer Center Researcher Receives NCI Outstanding Investigator Award to Study Two Deadly Blood Diseases
Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).
Rare cancer of immune cells linked to gene mutations in bone marrow and smoking
Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells, shows a study published today in eLife.
Multiple Myeloma – the Blood Cancer that Silently Impacts Vital Organs
Every year more than 1.3 million Americans will be living with, or be in remission from, a blood cancer. John Conti, M.D. discusses common symptoms and treatment.
White blood cells that can help destroy malignant tumors
A new study at Tel Aviv University found that eosinophils – a type of white blood cells – are recruited to the battle against cancer metastases in the lungs.
Blood Cancer Cures and Care: Addressing Leukemia and Lymphoma
Kevin David, MD the director of the lymphoma program and a hematologist/oncologist at Rutgers Cancer Institute of New Jersey shares information about leukemias and lymphomas for blood cancer awareness month.
Blood Cancers: Hidden Diseases with Many Treatments
When most people think about cancer, they tend to think of lumps and bumps, something visible they can see and touch. But with blood cancers, there are no immediate visible signs, just the effects of the cancer in the blood system. John Conti, M.D., explains more.
Understanding Lymphoma
Lymphoma is a rare form of cancer that affects bone marrow, lymph nodes, the thymus gland and spleen, collectively known as the lymphatic system. To understand more about lymphoma, we spoke with the co-medical director of the Cancer Program at Mountainside Medical Center, Lori Leslie, M.D.
Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
Low on Antibodies, Blood Cancer Patients Can Fight off COVID-19 with T Cells
Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
Studies suggest people with blood cancers may not be optimally protected after COVID-19 vaccination
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
Study finds risk of leukemia higher than expected in children with Down syndrome
The risk of childhood leukemia among kids with Down syndrome is higher than predicted, according to a new study led by UC Davis and UC San Francisco researchers. Early diagnosis remains critical.
scientists discover jumping genes that can protect against blood cancers
Surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases.
Promising role for whole genome sequencing in guiding blood cancer treatment
A new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient’s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing.
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Study: Treatment-related complication for blood cancer patients could be reduced
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.
Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.
Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting
Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.
Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome
A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.
New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.